Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 3:15 PM ET 5/24/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.72 | 1.12 | -35.76 |
| EPS, GAAP | 0.72 | 1.12 | 1.12 |
| Consensus Estimate | 0.70 | 1.07 | -33.98 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.57 | 3.95 | -9.58 |
| EPS, GAAP | 3.57 | 3.59 | -0.61 |
| Consensus Estimate | 3.71 | 4.34 | -14.55 |
| FRX | Industry Average | |
| P/E (TTM) | 9.08 | NA |
| P/E (Forward) | 35.77 | NA |
| PEG Ratio | 17.33 | 2.17 |
| Price/Sales | 2.01 | 4.18 |
| Beta | 0.70 | 0.62 |
| 3/29/2012 | Stocks to Watch: Collective Brands, Chelsea Therapeutics, Red Hat and More (WSJ.com) |
| 3/28/2012 | Amylin analysts advise caution amid stock run-up (MarketWatch.com) |
| 3/20/2012 | Stocks that give retirees what they want are incredibly valuable. (The Motley Fool) |
| 3/1/2012 | Mylan: Growth at a Reasonable Price (Barrons.com) |
| 2/29/2012 | Teva may be generic, but it's anything but ordinary. (The Motley Fool) |
| 2/23/2012 | Panel Supports Forest Labs Lung Drug (WSJ.com) |
![[sm061210things]](http://s.wsj.net/public/resources/images/PF-AC562_sm0612_C_20120514113337.jpg)
![[sm0612wedding4]](http://s.wsj.net/public/resources/images/PF-AC579_sm0612_C_20120515172853.jpg)
![[sm0612strat]](http://s.wsj.net/public/resources/images/PF-AC580_sm0612_C_20120515180019.jpg)
![[sm0612roi]](http://s.wsj.net/public/resources/images/PF-AC573_sm0612_C_20120515125902.jpg)
